A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma

To date, targeted therapy for pancreatic ductal adenocarcinoma (PDAC) remains largely unsuccessful in the clinic. Current genomics-based technologies are unable to reflect the quantitative, dynamic signaling changes in the tumor, and require larger tumor samples that are difficult to obtain in PDAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Kian-Huat, Langley, Emma, Gao, Feng, Luo, Jingqin, Li, Lin, Meyer, Gary, Kim, Phillip, Singh, Sharat, Kushnir, Vladamir M., Early, Dayna S., Mullady, Daniel K., Edmundowicz, Steven A., Wani, Sachin, Murad, Faris M., Cao, Dengfeng, Azar, Riad R., Wang-Gillam, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421844/
https://www.ncbi.nlm.nih.gov/pubmed/28445954
http://dx.doi.org/10.18632/oncotarget.15653

Ejemplares similares

Ejemplares similares